DARYL SHORTER to Cocaine-Related Disorders
This is a "connection" page, showing publications DARYL SHORTER has written about Cocaine-Related Disorders.
Connection Strength
2.707
-
Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant. Am J Drug Alcohol Abuse. 2020; 46(2):184-193.
Score: 0.576
-
The a-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals. Pharmacogenet Genomics. 2016 09; 26(9):428-35.
Score: 0.456
-
Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy. Expert Opin Emerg Drugs. 2015 Mar; 20(1):15-29.
Score: 0.404
-
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and a1A-adrenoceptor gene variation. Eur Neuropsychopharmacol. 2013 Nov; 23(11):1401-7.
Score: 0.367
-
The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study. Drug Alcohol Depend. 2013 Jul 01; 131(1-2):66-70.
Score: 0.354
-
Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med. 2011 Nov 03; 9:119.
Score: 0.326
-
Pharmacogenetics of Dopamine ?-Hydroxylase in cocaine dependence therapy with doxazosin. Addict Biol. 2019 05; 24(3):531-538.
Score: 0.127
-
Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend. 2014 Jul 01; 140:42-7.
Score: 0.097